Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CARVYKTI safely and effectively. See full prescribing information for CARVYKTI. CARVYKTI ®(ciltacabtagene autoleucel) suspension for intravenous infusion Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-other
CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
- generic_name
- ciltacabtagene autoleucel
- product_names
- ciltacabtagene autoleucel
- ndc
- 57894-111, 57894-111-01, 57894-111-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en